RITUXIMAB AND PLASMA EXCHANGE DOES NOT PREVENT DISEASE RECURRENCE IN HIGH RISK FSGS FOLLOWING LIVING DONOR TRANSPLANTATION

Shenoy Mohan; Kaur Amrit; Lennon Rachel; Webb Nicholas; Plant Nicholas

首页> 外文期刊>Pediatric nephrology: journal of the International Pediatric Nephrology Association >RITUXIMAB AND PLASMA EXCHANGE DOES NOT PREVENT DISEASE RECURRENCE IN HIGH RISK FSGS FOLLOWING LIVING DONOR TRANSPLANTATION

【24h】

RITUXIMAB AND PLASMA EXCHANGE DOES NOT PREVENT DISEASE RECURRENCE IN HIGH RISK FSGS FOLLOWING LIVING DONOR TRANSPLANTATION

机译：在活体移植后，Rituximab和血浆交换不会预防高危FSG的疾病复发

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Pediatric nephrology: journal of the International Pediatric Nephrology Association》 |2017年第9期|共1页
作者
Shenoy Mohan; Kaur Amrit; Lennon Rachel; Webb Nicholas; Plant Nicholas;
展开▼
作者单位

Royal Manchester Childrens Hosp Manchester Lancs England;

Royal Manchester Childrens Hosp Manchester Lancs England;

Royal Manchester Childrens Hosp Manchester Lancs England;

Royal Manchester Childrens Hosp Manchester Lancs England;

Royal Manchester Childrens Hosp Manchester Lancs England;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类儿科学;
关键词
入库时间 2022-08-20 06:02:46

相似文献

外文文献
中文文献
专利

1. RITUXIMAB AND PLASMA EXCHANGE DOES NOT PREVENT DISEASE RECURRENCE IN HIGH RISK FSGS FOLLOWING LIVING DONOR TRANSPLANTATION [J] . Shenoy Mohan, Kaur Amrit, Lennon Rachel, Pediatric nephrology: journal of the International Pediatric Nephrology Association . 2017,第9期

机译：在活体移植后，Rituximab和血浆交换不会预防高危FSG的疾病复发
2. Pre-emptive rituximab and plasma exchange does not prevent disease recurrence following living donor renal transplantation in high-risk idiopathic SRNS [J] . Trends in Ecology & Evolution . 2020,第6期

机译：先发制人的利妥昔单抗和血浆交换不会在高危作业性SRNS中活体肾移植后妨碍疾病复发
3. Pre-emptive rituximab and plasma exchange does not prevent disease recurrence following living donor renal transplantation in high-risk idiopathic SRNS [J] . Pediatric nephrology: journal of the International Pediatric Nephrology Association . 2020,第6期

机译：先发制人的利妥昔单抗和血浆交换不会在高危作业性SRNS中活体肾移植后妨碍疾病复发
4. Newly developed preconditioning regimen consisting of rituximab, splenectomy and plasmapheresis for non-responders to conventional regimen in ABO-incompatible kidney transplantation [C] . Satoshi Teraoka, Koutaro Kai, Kazuhiro Iwato, Nihon Ishoku Gakkai . 2006

机译：新开发的预处理方案，由rituximab，脾切除术和血浆的非响应者对常规方案组成，在Abo-Indompative肾移植中
5. Splenectomy in living donor liver transplantation and risk factors of portal vein thrombosis [D] . Kurata Nobuhiko, 倉田信彦 2019

机译：活体供体肝脾切除术及门静脉血栓形成的危险因素
6. Rituximab Induction to Prevent the Recurrence of PSC After Liver Transplantation—The Lessons Learned From ABO-Incompatible Living Donor Liver Transplantation [O] . Yohei Yamada, Ken Hoshino, Yasushi Fuchimoto, 2018

机译：利妥昔单抗诱导预防肝移植后PSC的复发-从与ABO不相容的活体供体肝移植中学到的教训
7. Late Reoccurrence of Collapsing FSGS After Transplantation of a Living-Related Kidney Bearing APOL 1 Risk Variants Without Disease Evident in Donor Supports the Second Hit Hypothesis [O] . Roberto S. Kalil, MD, Richard J. Smith, MD, Prerna Rastogi, MD, PhD, 2017

机译：FsGs活体肾脏移植后移植后塌陷的FsGs晚期复发1供体中无疾病的风险变异支持第二次命中假设

RITUXIMAB AND PLASMA EXCHANGE DOES NOT PREVENT DISEASE RECURRENCE IN HIGH RISK FSGS FOLLOWING LIVING DONOR TRANSPLANTATION

著录项

相似文献

相关主题

期刊订阅